Using tumor cell responses to guide therapy decisions
Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance
This study is testing if analyzing tumor cells can help doctors choose the best treatments for patients with different types of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Travera Inc Industry-sponsored |
| Locations | 1 site (Oakland, California) |
| Trial ID | NCT05461430 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate the mass response biomarker as a predictor of patient response to specific therapies or combinations. It involves collecting isolated tumor cells from various specimen formats, including malignant fluids like pleural effusions and ascites, as well as tissue biopsies and resections. The study will analyze these samples to determine their effectiveness in guiding treatment decisions for patients diagnosed with different types of carcinoma.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of any carcinoma who are undergoing therapy and have clinically indicated fluid drainage or tissue sampling.
Not a fit: Patients who are unable to provide informed consent or those from whom sufficient samples cannot be obtained may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for cancer patients.
How similar studies have performed: While the specific approach of using mass response biomarkers is novel, similar studies have shown promise in utilizing tumor cell analysis for therapy guidance.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient is ≥18 years of age 2. Written Informed Consent provided by patient 3. Diagnosis of any kind of carcinoma 4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC 5. Proceeding onto therapy for treatment 6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088) Exclusion Criteria: 1. Lack of informed consent 2. Unable to obtain sufficient sample
Where this trial is running
Oakland, California
- xCures — Oakland, California, United States (Recruiting)
Study contacts
- Principal investigator: Mark Stevens, Phd — Travera Inc
- Study coordinator: Mark Stevens, Phd
- Email: mstevens@travera.com
- Phone: 6172999784
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.